Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2010

View Archived Issues

Schering and Southern Research Institute claim new therapeutics for HCV infection

GlaxoSmithKline identifies new HIF-PH inhibitors for treatment of anemia

GlaxoSmithKline discovers novel IFN-alpha inducers

Canadian researchers claim new androgen receptor antagonists for prostate cancer

FibroGen discovers novel HIF prolyl hydroxylase inhibitors

Preclinical data support therapeutic potential of AGS-16M8F in kidney and liver cancer

Macrophage migration inhibitory factor inhibitors active in bladder cancer, diabetes models

Interim data of phase I/II AGS-003 trial in mRCC show promising immune and clinical response

Interim clinical data on varenicline for smoking cessation in bipolar depression disclosed

Asenapine reduces depressive symptoms in bipolar I disorder

GW's Sativex advances towards approval in U.K. and Spain for spasticity due to MS

Regenerative Medicine Assets sells ICX-TRC hair regeneration therapy to Aderans Research Institute

MediciNova reports preliminary phase Ib results on MN-221 in COPD

CPEX presents preliminary phase IIa results of Nasulin in type 2 diabetes

FDA schedules Joint Advisory Committee Meeting regarding Acurox NDA

Biomarkers Consortium launches I-SPY 2 breast cancer trial

Achillion receives NIH grant to study antibacterials

Emisphere and Alchemia to develop oral formulation of fondaparinux anticoagulant

Pharming submits response to CHMP for Rhucin MAA for hereditary angioedema

Novelos discontinues development NOV-002 in NSCLC

Teva Pharmaceutical to acquire Ratiopharm

Stemedica files IND with FDA for phase I/II allogeneic mesenchymal stem cell trial for stroke

FDA approves Carbaglu for N-acetylglutamate synthase deficiency

PolyMedix begins phase Ib trial of PMX-60056 for reversal of heparin-induced anticoagulation

FDA approves Somaxon's Silenor for treatment of insomnia